



CIN No. : L24239DL2004PLC125888

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/40-A

26th November, 24

**To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051**

**To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Mumbai - 400 001**

Symbol: AKUMS

Scrip Code: 544222

Sub: Submission of additional details as per SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023


Ref: Our disclosure dated 19th November, 24 on Execution of Exclusive Master Sales Agreement with Caregen Co., Ltd

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (SEBI Regulation) we would like to inform you that Akums Drugs and Pharmaceuticals Limited ("the Company/Akums") has entered into an exclusive Master Sales Agreement with Caregen Co., Ltd ("Caregen"), a leading South Korean company in Nutraceuticals segment.

Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement. Further the company shall also undertake the packaging, marketing and selling of Caregen's line of bulk product under the Caregen's trademark or Akums's trademark or of Akums's Clients trademark.

Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products.



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P





CIN No. : L24239DL2004PLC125888

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023 are provided herein as **Annexure-A**.


This is for your kind information and record.

Thanking You

Your faithfully

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Company Secretary & Compliance Officer



ISO 9001 : 2015
ISO 14001 : 2015
ISO 17025 : 2005 (NABL)

WHO-GMP
US : NSF
H A C C P



AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Annexure A

Sr. No.	Particulars	Details
1.	Name of the entity with whom agreement is signed	Caregen Co., Ltd ("Caregen")
2.	Area of agreement	Exclusive Master Sales Agreement
3.	Domestic/International	Domestic
4.	Share exchange ratio	Not Applicable
5.	Scope of business operation of agreement	Exclusive sale of Caregen products in India
6.	details of consideration paid / received in agreement	Not Applicable
7.	Significant Terms and Conditions of agreement	Significant terms & conditions: a) Caregen to exclusively supply bulk quantities of the Products to Akums for resale, packaging, and distribution in India b) Caregen will not sell the Products directly or indirectly to any other party in India c) This Agreement shall be effective for Five (05) years from the signing date. d) Caregen shall provide all necessary documentation, information, or assistance reasonably requested by regulatory authorities to support Akums in regulatory compliance and obtaining Permits for the Product in India
8.	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not Applicable
9.	Size of the entity	Overview: Caregen, a global leader in peptide research and development, is a global biotechnology company that has commercialized the unlimited expandability of its patented

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

		<p>peptides as many innovative products since its establishment in 2001. Over 600 different functional peptides developed by Caregen for the past 19 years have opened new paradigm in the field of biotechnology by expanding its applications to cosmeceutical, Class III medical devices, food supplement, and pharmaceuticals.</p> <p>Revenue: USD 58.5 million</p> <p>Market Cap: USD 773 million</p> <p>Country: South Korea</p>
10.	Rationale and benefit expected.	<p>Akums has been granted the exclusive rights to sell certain Caregen products range, in India, during the term of the agreement. Akums shall also undertake the packaging, marketing and selling of Caregen's line of bulk product under the Caregen's trademark or Akums's trademark or of Akums's Clients trademark.</p>



ISO 9001 : 2015
 ISO 14001 : 2015
 ISO 17025 : 2005 (NABL)

WHO-GMP
 US : NSF
 HACCP

